LONDON, ONTARIO--(Marketwire - Sept. 11, 2012) - Critical Outcome Technologies Inc. (COTI) (COT.V) announced today that an employee and a consultant were each granted 200,000 share options from the Company's Stock Option Plan as part of the compensation under their respective employment and consulting agreements on September 10, 2012. These 400,000 options have a life of five years and are exercisable at a price of $0.14 per share with vesting occurring immediately. The exercise price represents the closing price of the Company's common shares on Friday, September 7, 2012, the last reported trade on the TSX Venture Exchange prior to the approval date.
About Critical Outcome Technologies Inc. (COTI)
COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS(R), utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, please visit our website www.criticaloutcome.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Investment & Company Information
- TSX Venture Exchange